# Virtual Starr Cancer Consortium Retreat

Hosted online by Cold Spring Harbor Laboratory, May 3 – May 4, 2021

**Monday, May 3, 2021**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 am</td>
<td><strong>Welcome and Opening Remarks</strong></td>
<td>Bruce Stillman</td>
<td>President of Cold Spring Harbor Laboratory</td>
</tr>
<tr>
<td>9:10 am – 12:00 noon</td>
<td><strong>Plenary Session - 1</strong></td>
<td></td>
<td>Chairs: Richard Lifton &amp; Angela Koehler</td>
</tr>
<tr>
<td>9:10 am</td>
<td>1 Rona Yaeger</td>
<td>Defining Key Genomic Alterations in the Carcinogenesis of Colitis-Associated Cancers</td>
<td></td>
</tr>
<tr>
<td>9:35 am</td>
<td>2 Steven Lipkin</td>
<td>Lynch Syndrome Colorectal Cancer Immunoprevention using Recurrent Neoantigen Peptide Vaccination</td>
<td></td>
</tr>
<tr>
<td>10:00 am</td>
<td>3 Lisa Giulino Roth</td>
<td>Modulation of viral latency in EBV-associated lymphomas as a mechanism to sensitize tumors to EBV-directed cellular therapy</td>
<td></td>
</tr>
<tr>
<td>10:45 am</td>
<td>4 Scott Keeney</td>
<td>Genomic instability in the chromosomal context of physiological DNA double-strand break formation</td>
<td></td>
</tr>
<tr>
<td>11:10 am</td>
<td>5 Bishoy Faltas</td>
<td>APOBEC mutagenesis in bladder cancer: mechanisms and therapeutic opportunities</td>
<td></td>
</tr>
<tr>
<td>11:35 am</td>
<td>6 Marcin Imielinski</td>
<td>Deciphering signatures of broken DNA repair pathways in long-range cancer whole genome sequences</td>
<td></td>
</tr>
<tr>
<td>12:00 – 2:00 pm</td>
<td><strong>Poster Session (2 hours over lunch)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 – 5:00 pm</td>
<td><strong>Plenary Session - 2</strong></td>
<td></td>
<td>Chairs: Todd Golub &amp; Zsofia Stadler</td>
</tr>
<tr>
<td>2:00 pm</td>
<td>7 Sanford Simon</td>
<td>High Throughput Identification of Apoptosis Sensitizing Compounds in Fibrolamellar Hepatocellular Carcinoma</td>
<td></td>
</tr>
<tr>
<td>2:25 pm</td>
<td>8 Anne Carpenter</td>
<td>Using morphological pharmacodynamic markers to analyze drug sensitivity, resistance, and toxicity</td>
<td></td>
</tr>
<tr>
<td>2:50 pm</td>
<td>9 Kayvan Keshari</td>
<td>Imaging and targeting glycolytically driven oxidative stress using ascorbate</td>
<td></td>
</tr>
</tbody>
</table>
**Break (20 minutes)**

3:35 pm  10  Samie Jaffrey  
*Real-time imaging of metabolic deregulation in cancer*

4:00 pm  11  Elaine Fuchs  
*Dissecting the Metabolic Regulation of Tumor Initiating Stem Cells*

4:25 pm  12  Kivanc Birsoy  
*Identification of transcriptional determinants of asparaginase sensitivity in leukemias*

**End of Day One**

**Tuesday, May 4, 2021**

9:00 am – 11:55 am  **Plenary Session - 3**  
*Chairs: Lewis Cantley & Ethel Cesarmen*

9:00 am  13  Charles Sawyers  
*Defining prostate cancer cells of origin through single cell profiling*

9:25 am  14  Coraline Mlynarczyk  
*Defining the cellular origin and mechanistic basis for therapy resistant B-cell lymphomas*

9:50 am  15  Yi-Chieh Nancy Du  
*The function and regulation of MiT/TFE activation in autophagy and pancreatic ductal adenocarcinoma*

**Break (20 minutes)**

10:35 am  16  Gina Lee  
Hong-Wen Tang  
*Biochemical and genetic investigation of oncogenic TOR-dependent regulation of RNA metabolism and tumorigenesis using cross-species approaches*

11:00 am  17  Michael Kharas  
*The mRNA methylation program in leukemia*

11:25 am  18  Abhishek Niroula  
*Clonal Hematopoiesis as a Driver of Adverse Clinical Outcome*

11:55 am  **Closing Remarks**  
David Spector  
Director of Research  
Cold Spring Harbor Laboratory
Poster Presentations

Posters will be viewable on CSHL’s Virtual Poster Gallery, which will go live at 9am on Monday May 3 and remain available through end of day Tuesday May 4. Posters are numbered and cross-linked to the respective abstract and Slack sub-channel.

In the Virtual Poster Gallery, the posters are searchable by name, presenter or abstract. Posters are arranged randomly to maximize interaction (every browser view is different). Posters can be marked as viewed or marked for future reference.

Poster Session: Monday, May 3 12:00 pm – 2:00 pm

Abstract

19 Ayala Carl
Alexander Settle
Visualizing targeted killing of cancer cells by therapeutic T-cells at the nanoscale

20 Amanda J Pickard
Ruben Ramos
Detection of impending infections in immunocompromised cancer patients

21 Andrew Intlekofer
Metabolic coupling of hypoxia to intratumoral heterogeneity

22 Charles Kinzig
The role of telomerase in healing broken chromosomes in cancer

23 Helena Yu
Lior Golomb
Tikvah Hayes
EGFR inhibition in lung cancer: resistance, sensitization, and combination therapy

24 Steven Gross
Microbiome-derived Hydrogen Sulfide as a Trigger for CIMP Colorectal Cancer

25 Christopher Vakoc
Chemical disruption of kinase-to-chromatin signaling in chemotherapy-refractory leukemia

26 Cem Meydan
Dietary regulation of cancer immunity

27 Tai-Yuan Yu
Modifiers of BRCA2 Tumor Suppressor Loss of Function

28 Jasmin Kruell
Becky Leifer
Targeting the MYB Proto-Oncoprotein as a Therapeutic Strategy for Acute Myeloid Leukemia
29 Caroline Wiggers  
Exploiting functional epigenomics and proteomics to unravel neoantigens in pediatric leukemia

30 Alexia Martínez de Paz  
Mechanisms of dynamic chromatin reorganization regulating B cell differentiation and lymphomagenesis

31 Stefan Torborg  
Defining the cancer stem cell niche

32 Michael Ortiz  
Characterizing the genomic landscape of adult onset Wilms' tumors to generate faithful preclinical models for therapeutic testing

33 Yuhki Saito  
Systematic identification of oncogenic protein-RNA interaction sites for GBM treatment

34 Yang Bai  
Examining the link between EZH2 and chromosomal instability in metastatic breast cancer

35 Zsofia Stadler  
MSIPredict: Highly Sensitive Detection of Tumor Derived Cell-free DNA for Cancer Interception in Lynch Syndrome

36 Samantha J. Van Nest  
The Effects of Radiotherapy on the Presentation of Phosphorylated Antigens by Cancer Cells

37 Bishoy Faltas  
Defining the functional impact of composite mutations in oncogene-driven urothelial cancer using circulating-tumor DNA and single-cell sequencing

38 Hans-Guido Wendel  
Inhibitors of the elf4A RNA helicase for cancer therapy

39 Sun-Mi Park  
Targeting IKZF2 as a novel stem cell/immuno-oncologic therapy in AML

David Miyamoto

40 Alexey A Soshnev  
Elucidating the Etiologic Role of Linker Histone Mutations in Hematological Malignancy
<table>
<thead>
<tr>
<th>Page</th>
<th>Name</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>41</td>
<td>Coraline Mlynarczyk</td>
<td><em>Defining the cellular origin and mechanistic basis for therapy resistant B-cell lymphomas</em></td>
</tr>
<tr>
<td>42</td>
<td>Dylan McNally</td>
<td><em>Highly multiplex tissue imaging of b-cell lymphomas identifies novel pathological features predictive of overall survival</em></td>
</tr>
<tr>
<td>43</td>
<td>Juhee Pae</td>
<td><em>Cyclin d3 drives inertial cell cycling in dark zone germinal center b cells</em></td>
</tr>
<tr>
<td>44</td>
<td>Haley Noonan</td>
<td><em>An in vivo CRISPR Screen for Melanoma Progression in Zebrafish</em></td>
</tr>
</tbody>
</table>